Inhibikase Therapeutics Reports Second Quarter Financial Results, Highlights Recent Period Activities

Company to Host Conference Call on August 15, 2024 at 8:00 a.m. ET

BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapies to alter the course of Parkinson’s disease (“PD”), Parkinson’s disease-related disorders, and other diseases of the Abelson tyrosine kinases, today reported financial results for the second quarter ended June 30, 2024 and highlighted recent developments.

“The first half of 2024 demonstrated the strength of our pipeline with the continued execution of key milestones for both risvodetinib (risvo) and IkT-001Pro,” said Dr. Milton H. Werner, President and Chief Executive Officer of Inhibikase. “We completed enrollment in The 201 Trial, evaluating risvo in untreated Parkinson’s disease, and expect the last patient to disengage from the study in September 2024. We expect to report topline data in November 2024. Additionally, 001Pro has advanced as a potential treatment for pulmonary arterial hypertension (PAH). We have filed our IND and plan to ramp up the 702 trial following IND approval. Finally, the manufacturing requirements for 001Pro necessary for potential approval are progressing with the continued development of a scalable process.”